View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
Sponsored by Oncology Therapeutic Development (OTD)

Phase I Study of Bromodomain Inhibitor OTX015 in Patients with Lymphoma or Multiple Myeloma

Free White Paper

Phase I Study of Bromodomain Inhibitor OTX015 in Patients with Lymphoma or Multiple Myeloma

By Oncology Therapeutic Development (OTD)

Phase I Study of Bromodomain Inhibitor OTX015 in Patients with Lymphoma or Multiple Myeloma

By Oncology Therapeutic Development (OTD)
Enter your details to receive the free paper:

This white paper describes the methods and findings of a dose-escalation, open-label, pharmacokinetic, Phase I study of bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma.

This first-in-class small molecule inhibitor specifically binds to bromodomain motifs BRD2, BRD3 and BRD4 of bromodomain and extraterminal (BET) proteins, inhibiting them from binding to acetylated histones, which occurs preferentially at super-enhancer regions that control oncogene expression.

Download this free white paper to find out more.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology